

# THE BIOPHARMACEUTICAL COMPETITIVENESS & INVESTMENT (BCI) SURVEY 2017

## LATAM SPECIAL REPORT

### About the Survey:

The survey measures the attractiveness of 10 countries in Latin America for investment by biopharmaceutical research-based companies. Countries

surveyed include: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama and Peru.

## COMPETITIVENESS AND INVESTMENT ENABLING FACTORS AVERAGE SCORES IN LATIN AMERICA



## BCI MAIN TAKEAWAYS FOR BUILDING SUSTAINABLE BIOECONOMIES



**Value of Policy**  
Implement comprehensive, consistent long-term policies that enable and support biopharmaceutical investment.



**Long-Term Vision**  
Minimize budget cuts and keep focus on long-term vision of becoming a hub for biopharmaceutical investment.



**Prioritizing Innovation**  
Prioritize innovation by committing to investment in R&D infrastructure



**Strategic Budget Management**  
Favor efficient and transparent management of healthcare budgets focused on beyond the pill and access-focused initiatives



**Regulatory Upkeep**  
Ensure regulations are aligned with scientific advancements, especially in the field of biotechnology and medicines, to ensure patient safety



**Clinical Trial Infrastructure**  
Attract clinical studies by investing in infrastructure and streamlining approval processes

# BCI SURVEY - LATIN AMERICA PERFORMANCE IN COMPARISON TO OTHER REGIONS.

Enabling Factors	Scientific Capabilities & Infrastructure	Clinical Research Conditions & Framework	The Regulatory System	Market Access & Financing	Effective Intellectual Property Protections	Overall scores
Middle East & Africa average	54%	61%	57%	53%	55%	57%
Latin America average	55%	62%	57%	58%	56%	59%
Asia Pacific average	62%	69%	59%	54%	63%	61%

## Key Insights of Regional Comparisons

Focusing on a handful of areas of reform does not lead to a thriving biopharmaceutical sector; instead, a holistic and comprehensive approach is required that addresses variables across the entire biopharmaceutical ecosystem.

Achieving and maintaining a successful healthcare system is not guaranteed by brute economic force or market size.



**1** LATAM, AP and MEA still have room for improvement and collectively are more or less at the same level – around 60% of the total possible score.

**2** LATAM, AP and MEA tend to face the most challenges in the areas of market access and regulatory systems – and in LATAM and MEA also in effectiveness of IP protections.

**3** LATAM, AP and MEA on average have the greatest strength in the area of clinical trials